Inflammation 149 items
Whether Lp(a) risk depends on inflammation (CRP, IL-6): the Copenhagen and biobank analyses, OxPL biology and what olpasiran does and does not change.
Studies
- The 2022 EAS consensus statement on Lp(a) in ASCVD and aortic stenosis (Kronenberg, Mora, Stroes et al., EHJ 2022)
- LPA is the genome-wide signal for aortic valve calcification and stenosis (Thanassoulis et al., NEJM 2013)
- KRAKEN: oral muvalaplin lowers Lp(a) by 82 to 86 percent on an intact-particle assay (Nicholls et al., JAMA 2025)
- Inflammation, cholesterol, Lp(a) and 30-year cardiovascular outcomes in women (Ridker et al., NEJM 2024)
- Lp(a) and oxidised phospholipids drive valve calcification activity and progression in aortic stenosis (Zheng et al., JACC 2019)
- Oxidised phospholipids on Lp(a) drive arterial wall inflammation and a primed monocyte response (van der Valk et al., Circulation 2016)
- First antisense drug against apo(a) in humans: ISIS-APO(a)Rx phase 1 (Tsimikas et al., Lancet 2015)
- Lp(a) raises cardiovascular risk regardless of hs-CRP, in primary and secondary prevention (Small et al., JAMA Cardiol 2024)
- Lp(a) drives ASCVD, MI and aortic stenosis risk independent of C-reactive protein: Copenhagen (Thomas et al., EHJ 2023)
- AHA scientific statement: Lp(a) is a genetically determined, causal and prevalent risk factor for ASCVD (Reyes-Soffer et al., ATVB 2022)
- Potent Lp(a) lowering with apo(a) antisense reduces pro-inflammatory activation of monocytes (Stiekema et al., EHJ 2020)
- Arterial wall inflammation persists in high-Lp(a) patients despite 60 percent LDL-C lowering with evolocumab (Stiekema et al., EHJ 2019)
- Oxidised phospholipids as a unifying theory for Lp(a) in ASCVD and aortic valve disease (Boffa and Koschinsky, Nat Rev Cardiol 2019)
- Lipoprotein(a): resurrected by genetics (Kronenberg and Utermann, J Intern Med 2013)
- IL-6 modifies Lp(a)-associated coronary risk but not aortic stenosis risk: UK Biobank (JAMA Cardiol 2026)
- Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)
- Lp(a) and interleukin-6 are independent, additive predictors of coronary events: MESA and UK Biobank (Bhatia et al., JACC 2025)
- One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)
- Olpasiran lowers oxidised phospholipids on apoB by about 90 percent without moving hs-CRP or IL-6: OCEAN(a)-DOSE (Rosenson et al., JAMA Cardiol 2025)
- LPA variants, apo(a) isoforms and events differ by ethnicity: the Dallas Heart Study (Lee et al., Circulation 2017)
- Lp(a) as a pharmacological target: premises, promises and prospects (Greco et al., Circulation 2025)
- Elevated hs-CRP, LDL-C and Lp(a) each independently predict 30-year stroke risk in healthy women, Women's Health Study finds (Lancet Neurol 2025)
- Combined LDL-C, Lp(a) and hsCRP identify highest ASCVD risk across ethnicities, multiethnic HELIUS cohort of 15,676 (J Am Coll Cardiol 2026)
- Lp(a) and oxidised phospholipids track myocardial inflammation after heart attack in a PCSK9-inhibitor trial (Nat Cardiovasc Res 2026)
- Lp(a), remnant cholesterol and hsCRP each independently add to MI risk prediction, UK Biobank cohort of 306,183 (Prog Cardiovasc Dis 2026)
- Lowering Lp(a) and IL-6 signalling together additively cuts coronary disease risk, Mendelian randomisation of 408,687 (Eur J Prev Cardiol 2026)
- Elevated Lp(a) independently predicts incident atrial fibrillation regardless of inflammatory status, 365,899-participant UK Biobank study finds (Heart Rhythm 2025)
- Colchicine's cardiovascular benefit in the LoDoCo2 trial was greatest in patients with elevated Lp(a), and even more clearly modified by oxidised phospholipids on ApoB (Eur J Prev Cardiol 2025)
- Autoimmune disease and elevated Lp(a) combine additively to nearly double MACE risk, 353,035-person UK Biobank analysis finds (Atherosclerosis 2025)
- Lp(a) activates monocytes via TLR2 and NF-kB to drive tissue factor expression, the first mechanistic link between Lp(a) and immunothrombosis, systems-biology study finds (J Lipid Res 2025)
- Elevated Lp(a) plus high hs-CRP together confer the highest ASCVD risk, pooled 15,933-person ARIC/FOS/MESA analysis finds, especially in men and at intermediate baseline risk (Nutrients 2025)
- Meta-analysis of 562,301 participants confirms Lp(a) raises MACE risk independent of hs-CRP in both primary and secondary prevention (JACC Adv 2024)
- In 10,000 PCI patients, elevated Lp(a) only predicts death when LDL-C and hs-CRP are both high (Clin Cardiol 2024)
- BiomarCaRE project of 71,678 people finds Lp(a) predicts recurrent coronary events only in those with residual inflammatory risk (Eur Heart J 2024)
- Autotaxin carried by Lp(a) drives aortic valve mineralization, raising valve autotaxin activity by 60% in diseased valves, a mechanistic study (Circulation 2015)
- Lp(a) barely changes after eating or with inflammation, and still predicts heart disease regardless, a Danish study of 34 829 people (Atherosclerosis 2014)
- Pro-inflammatory IL-1 genotype raises coronary disease risk from oxidized phospholipids seven-fold in younger patients, a study of 499 patients (J Am Coll Cardiol 2014)
- Oxidized phospholipids potentiate Lp(a) coronary risk two-fold when combined with high phospholipase A2 activity, an EPIC-Norfolk study of 763 cases and 1397 controls (J Am Coll Cardiol 2010)
- Oxidized phospholipids on Lp(a) predict 10-year cardiovascular events, amplified by a related enzyme activity, the Bruneck study of 765 people (Arterioscler Thromb Vasc Biol 2007)
- Lp(a) raises post-PCI cardiovascular risk mainly when pericoronary inflammation is high, machine-learning study (J Clin Lipidol 2026)
- Comparative associations of LDL-C, Lp(a), hsCRP, and IL-6 with cardiovascular risk: Insights from the UK Biobank and MESA
- IL-6 receptor signalling and Lp(a) independently lower cardiovascular risk, Mendelian randomisation study (JACC Basic Transl Sci 2026)
- IL-6 modifies whether Lp(a) predicts cardiovascular events, UK Biobank cohort of 34,092 (Atherosclerosis 2026)
- Lipoprotein(a), High-Sensitivity C-Reactive Protein, and Incident ASCVD Risk in Individuals Without Standard Modifiable Risk Factors
- Lp(a) reduction explains only a small part of IL-6 inhibition's cardiovascular benefit, Mendelian randomisation study (Atherosclerosis 2026)
- IL-6 inhibition lowers Lp(a), meta-analysis of 10 studies and 1,201 patients (Am J Prev Cardiol 2026)
- Lp(a) predicts ASCVD across glucose-metabolism status independent of CRP, UK Biobank cohort of 307,269 (Diabetes Obes Metab 2026)
- Tea's benefit after coronary heart disease is greatest when Lp(a) is low and CRP is high, UK Biobank analysis of 25,306 patients finds (Front Nutr 2026)
- Dual-high Lp(a) and inflammatory-lipid index carries an 8-fold MACE risk in 1,910 ACS patients with type 2 diabetes (Front Cardiovasc Med 2026)
- Lp(a)'s link to coronary stenosis holds only under low systemic inflammation, 1,513-patient angiography study finds (Am J Prev Cardiol 2025)
- Lp(a) drives coronary artery spasm through a CD36-RhoA-IL-6 inflammatory pathway that a natural biflavonoid can block, mechanistic study finds (Pharmaceuticals (Basel) 2025)
- Combining Lp(a) with CT-quantified pericoronary fat inflammation sharpens MACE prediction in non-obstructive coronary disease, 1,052-patient study finds (Int J Cardiol 2026)
- Elevated Lp(a) independently predicts ventricular arrhythmias, even after adjusting for ASCVD, TriNetX cohort of over 116,000 patients finds (Heart Rhythm O2 2025)
- IL-6, not hsCRP, unmasks Lp(a)- and oxidised-phospholipid-associated cardiovascular risk in the LoDoCo2 placebo arm (Atherosclerosis 2025)
- High IL-6, not hsCRP, amplifies the cardiovascular mortality risk of markedly elevated Lp(a), LURIC study of 3,316 angiography patients finds (Clin Res Cardiol 2025)
- Combined elevation of Lp(a), hs-CRP and homocysteine triples stroke risk in the Multi-Ethnic Study of Atherosclerosis (Am J Prev Cardiol 2025)
- NHANES III analysis finds high Lp(a) plus high fibrinogen together carry a 2.4-fold higher cancer mortality risk, not just cardiovascular risk (BMC Public Health 2024)
- Amsterdam UMC team finds Lp(a)-carried diacylglycerols drive monocyte inflammation via NLRP3, and pelacarsen lowers these specific lipids (Arterioscler Thromb Vasc Biol 2024)
- Lp(a) improves 20-year cardiovascular risk reclassification beyond the Framingham and Reynolds scores, the ATTICA study (J Clin Lipidol 2024)
- Combined elevation of Lp(a) and Lp-PLA2 raises 1-year stroke recurrence risk in 10,675 ischaemic stroke and TIA patients (J Clin Lipidol 2024)
- Lp(a) and its oxidised phospholipids predict multivessel coronary disease and cardiovascular events in 1,098 patients undergoing angiography, the CASABLANCA study (J Am Coll Cardiol 2023)
- High Lp(a) doubles coronary heart disease risk only in people with elevated Factor VIII or hs-CRP, an interaction found in 6,495 MESA participants (J Clin Lipidol 2023)
- Bempedoic acid modestly raises Lp(a) by 2.4% while lowering hsCRP by 26.5% and LDL-C by 21.1%, a CLEAR Harmony sub-analysis of 817 patients (J Clin Lipidol 2023)
- Elevated Lp(a) raises cardiac event risk only when hs-CRP is also high, an interaction found in 10,424 PCI patients (Atherosclerosis 2022)
- Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
- Lp(a)-related cardiovascular risk only appears when hs-CRP is also elevated, a MESA analysis of 4,679 participants (J Am Coll Cardiol 2021)
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial
- Inflammatory IL-1 genotype doubles the cardiovascular risk from high Lp(a), the Ioannina Study of 603 patients (J Clin Lipidol 2018)
- Tocilizumab lowers Lp(a) in rheumatoid arthritis patients, unlike other biologic therapies, the Spanish CARMA study of 775 patients (J Clin Lipidol 2017)
- Tocilizumab blocks IL-6 to lower Lp(a) via a specific LPA gene promoter site, but TNF-alpha inhibition does not, a mechanistic study (J Lipid Res 2015)
- Oxidized phospholipids bind apo(a) via a specific kringle site unique to humans, explaining Lp(a) pro-atherogenic potential, a mechanistic study (J Lipid Res 2013)
- Lp(a) carries over 85% of oxidized phospholipids in human plasma, a foundational mechanistic study (J Lipid Res 2008)
- Angioplasty acutely raises Lp(a) by 64% and oxidized phospholipids by 36%, a mechanistic study of 141 patients (Circulation 2004)
- High Lp(a) combined with chronic Chlamydia infection may worsen aortic valve stenosis, a Swedish study of 101 patients (Eur Heart J 2003)
- High CRP or Lp(a), but not homocysteine, predict adverse events after coronary stenting, a study of 483 patients followed 3 years (J Am Coll Cardiol 2002)
- Lp(a) does not predict peripheral artery disease, unlike CRP and the cholesterol ratio, a study of 14,916 physicians (JAMA 2001)
- A new antibody detects oxidized Lp(a) specifically, revealing higher levels in hypertensive patients with complications, a Japanese study (Circulation 2000)
- Lp(a) combined with Chlamydia antibodies in immune complexes nearly quadruples heart attack risk, a Swedish study of 78 cases and 156 controls (Eur Heart J 2000)
- CKD enriches Lp(a) with triacylglycerols, diacylglycerols and oxidised phospholipids, 54-patient lipidomic study (J Clin Lipidol 2026)
- High Lp(a) raises coronary heart disease risk only alongside high hsCRP in a 4128-person Chinese cohort (Clin Chim Acta 2026)
- Lp(a) and inflammation (CAR) jointly predict poor 90-day outcome after stroke in elderly patients, cohort of 732 (Lipids Health Dis 2026)
- Lp(a) is elevated across autoimmune diseases with limited evidence that anti-inflammatory therapy helps, systematic review of 13 studies (J Clin Lipidol 2026)
- Lp(a) drives coronary microvascular dysfunction via antifibrinolytic and oxidised-phospholipid pathways, review (Life Sci 2026)
- PCSK9 inhibition leaves monocyte subsets unchanged but Lp(a) composition tracks inflammatory monocytes after MI (Atheroscler Plus 2026)
- Lp(a) falls 21% within weeks of kidney transplant, unrelated to autotaxin activity, Polish cohort of 55 (Int J Mol Sci 2026)
- Lp(a) tracks with coronary inflammation in men with HIV and undetectable viral load, and statins do not blunt the link, MACS analysis finds (Eur Heart J Imaging Methods Pract 2026)
- Lp(a) drives atherosclerosis through endothelial injury, inflammation and impaired fibrinolysis, review (Eur Cardiol 2026)
- Lp(a) may be the mechanistic bridge between inflammation and excess cardiovascular risk in rheumatoid arthritis, review argues, with IL-6 blockade as a lever (J Clin Lipidol 2025)
- Updated meta-analysis confirms psoriasis patients have significantly higher Lp(a), with the gap twice as large in Europeans as in Asians (World J Clin Cases 2025)
- In patients 75 and older with established ASCVD, inflammation predicts MACE more strongly than Lp(a), 2,333-patient Fuwai Hospital study finds (Age Ageing 2025)
- High Lp(a) combined with elevated monocyte-to-HDL-C ratio predicts peripheral artery disease 9.5 years earlier, 361-patient study finds (Int J Mol Sci 2025)
- The Lp(a) paradox: high levels drive atherosclerosis but very low levels may raise type 2 diabetes risk, review argues for a risk-benefit reckoning (Diabetes Res Clin Pract 2025)
- From kringle IV type 2 copy number to arterial wall: the mechanistic biology of Lp(a) reviewed (Eur J Clin Invest 2026)
- Systemic sclerosis patients have higher Lp(a) and triglycerides but lower HDL-C than healthy controls, meta-analysis of over 2,500 participants finds (Rheumatol Int 2025)
- PCSK9 inhibitors curb endothelial inflammation triggered by Lp(a) itself, not just LDL, in coronary artery cell culture, mechanistic study finds (BMC Cardiovasc Disord 2025)
- Elevated Lp(a) combined with a high monocyte count carries the greatest risk of carotid plaque progression in premature coronary disease, 102-patient study finds (Diseases 2025)
- Serum Lp(a) is higher in rheumatic heart valve disease and tracks with mitral stenosis severity and valve involvement, 80-patient study finds a possible new link (Lipids 2025)
- Mendelian randomisation finds no causal link between Lp(a) and nine immune-mediated inflammatory diseases (Sci Rep 2025)
- Amsterdam UMC study finds high Lp(a) raises monocyte inflammation genes but not chromatin accessibility, pointing to a non-epigenetic mechanism (J Clin Lipidol 2025)
- PPARgamma suppresses IL-6-driven Lp(a) production in liver cells, and the diabetes drug pioglitazone can trigger that suppression (J Cardiovasc Pharmacol 2024)
- High Lp(a) plus high hs-CRP together confer a 4.74-fold risk of subclinical valve leaflet thickening after TAVR (J Am Heart Assoc 2024)
- Review by Borén and colleagues explains why Lp(a) is roughly six times more atherogenic than LDL per particle (Curr Opin Cardiol 2024)
- High neutrophil-to-lymphocyte ratio unmasks Lp(a)'s prognostic harm after PCI, especially in women, 7,922-patient study finds (Angiology 2025)
- Concurrent high Lp(a) and hs-CRP nearly quadruples cardiovascular death risk after acute myocardial infarction in 912 patients (Front Endocrinol 2024)
- Combined elevation of Lp(a) and hs-CRP, not Lp(a) alone, raises platelet reactivity on clopidogrel in 6,615 PCI patients (Clin Appl Thromb Hemost 2024)
- Interleukin-6 receptor inhibitors lower Lp(a) by 16-41%, less than dedicated Lp(a) drugs but with an added anti-inflammatory effect, a review (Atheroscler Plus 2023)
- Antisense oligonucleotides and siRNAs cut Lp(a) by 98-101% in recent trials, though whether this reduces cardiovascular events remains unknown, a review (Expert Rev Cardiovasc Ther 2023)
- High-dose omega-3 fatty acids cut arterial inflammation by 4% in patients with elevated Lp(a), an EPA-driven effect, a pilot PET/CT study of 12 patients (J Clin Lipidol 2023)
- Lp(a) rises with thrombotic activity but falls with inflammation during COVID-19 hospitalisation, with no link to mortality, in 211 Danish patients (Atherosclerosis 2022)
- Nano-curcumin (80 mg/day) cuts Lp(a) and hs-CRP over 90 days in 64 type 2 diabetic patients with coronary artery disease, an RCT (Biofactors 2023)
- The LPA gene IL-6 response elements make Lp(a) an inflammatory driver, not just a lipid particle, at levels above 125 nmol/L, a review (Atherosclerosis 2022)
- LPA shares up to 70% of its sequence with plasminogen, explaining Lp(a) triple threat of atherosclerosis, thrombosis and inflammation, a review (Biomolecules 2022)
- Lp(a) surges during COVID-19 hospitalisation and those with the biggest rise face a 3-fold higher risk of blood clots, a Dutch pilot study of 219 patients (Atherosclerosis 2022)
- Bariatric surgery paradoxically raises Lp(a) by 66% while cutting oxidised-phospholipid markers, a prospective study of 59 patients (J Clin Lipidol 2021)
- Conjugated linoleic acid supplements raise both CRP and Lp(a) levels, a meta-analysis of 21 randomised trials (Iran J Med Sci 2019)
- Blocking IL-6 with tocilizumab does not lower Lp(a) in heart attack patients, a randomised trial of 117 NSTEMI patients (Int J Cardiol 2019)
- Elevated Lp(a) shifts monocytes toward a more inflammatory subset, a study of 90 patients with stable coronary disease (J Clin Lipidol 2015)
- Lp(a) carries the inflammatory chemokine MCP-1 in human plasma via oxidized phospholipids, a mechanistic study (J Lipid Res 2013)
- Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease
- Oxidised phospholipids and autotaxin link Lp(a) to aortic valve calcification, mechanistic review (Int J Mol Sci 2026)
- Markedly elevated Lp(a) unmasks vulnerable plaque missed by a zero calcium score, case report in sarcoidosis (J Clin Lipidol 2026)
- Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk
- Monocyte-to-HDL and lymphocyte-to-monocyte ratios track with high Lp(a) in healthy adults, diagnostic accuracy study (Acta Cardiol Sin 2026)
- Mass-spectrometry method changes the Lp(a) proteome, but a 34-protein core is method-independent (J Clin Med 2026)
- High-risk Lp(a) above 50 mg/dL is nearly twice as common in inflammatory bowel disease patients as in matched controls (Med Clin (Barc) 2026)
- Lp(a) is significantly higher in Crohn's disease and ulcerative colitis than in healthy controls, meta-analysis of 1,978 participants finds (Ann Gastroenterol 2026)
- Lp(a) may drive diabetic kidney disease via TGF-beta fibrosis and podocyte injury, review of unresolved mechanisms (Diabetes Res Clin Pract 2026)
- Serum Lp(a) predicts endothelial dysfunction in 123 hemodialysis patients, with AUC up to 0.853 for poor vascular reactivity (Ren Fail 2025)
- LDL-C and Lp(a) push monocytes and macrophages into a self-perpetuating foam-cell-forming, pro-inflammatory cycle, review explains (Biochem Med (Zagreb) 2025)
- In severe aortic stenosis, Lp(a) does not track with valve calcium and shows only a modest, male-specific link to fibrosis, CT and cytokine study finds (J Transl Med 2025)
- Children with Prader-Willi syndrome have markedly higher Lp(a) and hs-CRP than controls, with the deletion genetic subtype most affected, 32-patient study finds (J Endocr Soc 2025)
- Combining Lp(a) with hs-CRP raises coronary heart disease diagnostic AUC to 0.924, beating either marker alone (Am J Transl Res 2025)
- Review explores Lp(a)'s dual role in both driving and, in some contexts, dampening the inflammation behind atherosclerosis (Curr Atheroscler Rep 2024)
- Periodontal inflammation area correlates with both IL-6 and Lp(a) in diabetic patients, more strongly in those with retinopathy (World J Diabetes 2024)
- An Lp(a) gene haplotype (rs10455872-rs3798220) is linked to higher inflammation and antifibrinolytic markers after myocardial infarction (Int J Mol Sci 2024)
- Higher Lp(a) and TG/HDL-C ratio flag unstable carotid plaque in 142 acute ischaemic stroke patients (Brain Behav 2024)
- Lp(a) is linked to greater peri-coronary inflammation in people with HIV compared to those without, in a study of 79 participants (J Clin Lipidol 2024)
- Lp(a) cardiovascular risk may run through inflammation, and lowering it partly reverses the inflammatory profile, a review (J Clin Lipidol 2023)
- How much do oxidised phospholipids explain Lp(a) danger, and can drugs lower them? An update review (Eur J Clin Invest 2022)
- IL-6 receptor blockade with tocilizumab reverses high Lp(a) in rheumatoid arthritis, hinting at an inflammatory route to Lp(a) control, a review (Pharmacol Res 2021)
- Could Lp(a) explain COVID-19 clotting complications? A Dutch-led team proposes IL-6-driven Lp(a) surges as a testable hypothesis (Curr Atheroscler Rep 2020)
- Apo(a)-targeted drugs can lower Lp(a) by up to 90%, a review of Lp(a) mechanisms in atherosclerosis and aortic stenosis (Hellenic J Cardiol 2020)
- Lp(a) and inflammation together erode endothelial integrity, a review of their dangerous interaction (Pharmacol Res 2017)
- Lp(a) carries an enzyme that degrades oxidized phospholipids, a review of lipoprotein-associated phospholipase A2 (Arterioscler Thromb Vasc Biol 2007)
- Lp(a)-monocyte associations differ by race in single-cell RNA-seq analysis, 34-participant preprint study (bioRxiv 2026)
- Lipid-lowering therapy reduces oxidised-apoB immune complexes but not other oxidative markers in patients with Lp(a) 75 nmol/L or more (Clin Res Cardiol 2026)
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target
- Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients
- Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort